Aug 21 - Aug 27  ' 2019
Editor's Note


Gubba Pharma e-News is a weekly newsletter for the pharmaceutical industry from Gubba Cold Storage. We aim to update you with quality news pertaining to the industry.  Hope you enjoy reading this issue, and every issue !

Gubba Kiran,
Gubba Cold Storage
Alembic Pharmaceuticals gets USFDA nod for ophthalmic solution

The approved product is therapeutically equivalent to the reference listed drug (RLD), Bromday Ophthalmic Solution, 0.09 percent, of Bausch & Lomb. Drug firm Alembic Pharmaceuticals on June 24 said it has received approval from the US health regulator for Bromfenac Ophthalmic Solution, used for treatment of post-operative inflammation and reduction of ocular pain. ..
News @ Gubba

New LinkedIn avatar for Gubba
Like our linkedin page at below link to get latest industry updates. We have upgraded to a new avatar for sharing prominent information about cold storage preservation.
Novartis wins EU approval for blood cancer therapy Kymriah

Novartis has received European approval for Kymriah, its gene-modifying therapy for blood cancer, but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity. The company aims initially to use the therapy in Europe for young people up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL), and later for adult patients with diffuse large B-cell lymphoma (DLBCL). . .

Sun Pharma In Rs. 240-Crore Licensing Pact With IICT Hyderabad

Sun Pharmaceutical Industries has entered into a Rs. 240-crore global licensing deal with the Indian Institute of Chemical Technology, Hyderabad under the Council of Scientific and Industrial Research Indian (CSIR) for developing new drugs... 
Share news, happenings, events, launches and anything about your company and the Pharmacuetical industry. Gubba will be more than glad to receive and publish them.... Please mail your information at                                         

Disclaimer: The content is based on reporting in reputed publications including newspapers and is for information only. Gubba does not support or subscribe to the content.